Programmed death ligand 1 (PD-L1) on IHC revealed a tumor proportion score (TPS) of 2% and next-generation sequencing (NGS), performed on the tumor tissue, revealed two in cis mutations of the EGFR gene: S768I, with a variant allele frequency (VAF) of 43.2%; and V774M, with a VAF of 43.6%. This evidence concerns the gene EGFR and neoplasm.